Eli Lilly and Company (NYSE:LLY) Stock Rating Lowered by Wall Street Zen

robot
Abstract generation in progress

Wall Street Zen has downgraded Eli Lilly and Company’s stock rating from “strong-buy” to “buy” despite recent positive developments like the FDA approval of Foundayo and strong quarterly earnings. The article also notes other analyst actions, current stock performance data, and significant institutional investor activity. While Eli Lilly continues to expand its pipeline with acquisitions and new drug approvals, competitive pressures and broader market risks are highlighted.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin